THAR

Investor Moves

Name	Value	Action	Change	Price	Current Price
Jim SimonsRenaissance Technologies $-6 ExitQ2 2024 $6 -- --
Jim SimonsRenaissance Technologies $-6 ExitQ2 2024 $6 -- --

News

defenseworld.netTharimmune Highlights Canton Network Q1 Growth, Tokenomics Shift and Validator Locking in Webinardefenseworld.netApr 27

Trade THAR

About Tharimmune, Inc.

Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. Its preclinical immuno-oncology portfolio includes several product candidates: TH104, aimed at treating inflammatory conditions linked to the liver and other causes of itching; TH3215 and TH0059, which are designed to address a variety of solid tumors; and TH1940, specifically targeting programmed cell death protein 1 (PD-1). Furthermore, the company has entered into a research collaboration and product license agreement with Minotaur Therapeutics, Inc. to develop proprietary targeted biologics. Originally incorporated in 2017 as Hillstream BioPharma, Inc., the company rebranded to Tharimmune, Inc. in September 2023 and maintains its headquarters in Bridgewater, New Jersey.

CEO: Mark Wendland
IPO Date: Jan 12, 2022

Market Data

Open: $3.34
High: $3.58
Low: $3.32
Volume: 358.8K
Avg Volume: 807.9K
52W High: $9.08
52W Low: $0.952

Valuation

Market Cap: $140M
Enterprise Value: $76M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-16M
Revenue: $0
Net Income: $-36M
Cash: $17M
Debt: $0

Events

EarningsJun 3